Jurnista (Hydromorphone Hydrochloride)

Hydromorphone is an opioid analgesic used for pain management across several clinical settings.

• Moderate to severe acute pain: provides rapid relief of intense pain episodes.
• Postoperative pain: helps control pain following surgical procedures.
• Cancer‑related pain: alleviates persistent pain associated with malignant disease.

• Hydromorphone acts as a potent μ‑opioid receptor agonist in the central nervous system. By binding to these receptors, it inhibits the transmission of nociceptive signals and alters pain perception, producing analgesia. The drug also reduces the release of neurotransmitters involved in pain pathways, contributing to its strong analgesic effect.

Hydromorphone may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Constipation: reduced gastrointestinal motility.
• Nausea: feeling of queasiness or urge to vomit.
• Drowsiness: increased sleepiness or fatigue.
• Dry mouth: reduced salivary flow.
• Dizziness: light‑headed sensation.
• Pruritus: mild itching of the skin.

Serious or Rare Side Effects

• Respiratory depression: slowed or shallow breathing.
• Severe hypotension: marked drop in blood pressure.
• Dependence or addiction: potential for misuse with prolonged use.
• Seizures: rare occurrence of convulsive episodes.
• Anaphylaxis: life‑threatening allergic reaction.
• QT prolongation: abnormal heart rhythm in susceptible individuals.

When prescribing hydromorphone, clinicians should consider several safety measures.

• Assess pain severity: confirm that pain is moderate to severe before initiating therapy.
• Evaluate respiratory function: monitor patients with compromised breathing.
• Review opioid history: avoid use in individuals with known opioid dependence.
• Adjust for renal/hepatic impairment: dose may need modification in organ dysfunction.
• Educate on constipation: advise prophylactic laxatives and hydration.
• Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Hydromorphone can interact with other medications, influencing its safety and efficacy.

Major Interactions (Avoid)

• CNS depressants (e.g., benzodiazepines, barbiturates): may cause profound respiratory depression.
• MAO inhibitors: can precipitate severe hypertension or serotonin syndrome.
• CYP3A4 inhibitors (e.g., ketoconazole): increase hydromorphone plasma levels.

Moderate Interactions (Monitor Closely)

• CYP2D6 inhibitors (e.g., fluoxetine): may modestly raise drug concentrations.
• Anticholinergics: may worsen constipation.
• Diuretics: can enhance hypotensive effects.
• Alcohol: additive sedative effect, requires caution.